Table 1 Demographic and clinicopathologic characteristics in training and validation cohorts (GSE62254)
From: A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma
Variables | Training | Validation | P value |
|---|---|---|---|
N | 172 | 86 | |
Sex | |||
Female | 61 (35.5) | 24 (27.9) | 0.281 |
Male | 111 (64.5) | 62 (72.1) | |
Age (years) | |||
≤ 65 | 105 (61.0) | 43 (50.0) | 0.119 |
> 65 | 67 (39.0) | 43 (50.0) | |
Signet ring | |||
No | 144 (83.7) | 77 (89.5) | 0.286 |
Yes | 28 (16.3) | 9 (10.5) | |
Perineural invasion | |||
No | 87 (63.0) | 51 (68.9) | 0.481 |
Yes | 51 (37.0) | 23 (31.1) | |
Lymphovascular invasion | |||
No | 43 (27.2) | 21 (25.9) | 0.953 |
Yes | 115 (72.8) | 60 (74.1) | |
T stage | |||
2–3 | 113 (65.7) | 57 (66.3) | 0.817 |
4a | 50 (29.1) | 26 (30.2) | |
4b | 9 ( 5.2) | 3 ( 3.5) | |
N stage | |||
0 | 19 (11.0) | 13 (15.1) | 0.755 |
1 | 37 (21.5) | 16 (18.6) | |
2 | 45 (26.2) | 22 (25.6) | |
3a | 42 (24.4) | 24 (27.9) | |
3b | 29 (16.9) | 11 (12.8) | |
Number of positive lymph nodes | 8.06 ± 9.27 | 7.87 ± 9.96 | 0.879 |
Lauren | |||
diffuse | 81 (47.1) | 30 (34.9) | 0.126 |
intestinal | 79 (45.9) | 51 (59.3) | |
mixed | 12 ( 7.0) | 5 ( 5.8) | |
Tumor location (%) | |||
Cardia/Upper | 19 (11.0) | 7 ( 8.1) | 0.613 |
Middle | 65 (37.8) | 30 (34.9) | |
Antrum/Distal | 88 (51.2) | 49 (57.0) | |
ACRG.sub (%) | |||
EMT | 25 (14.5) | 10 (11.6) | 0.809 |
MSI | 41 (23.8) | 24 (27.9) | |
TP53neg | 59 (34.3) | 31 (36.0) | |
TP53positive | 47 (27.3) | 21 (24.4) | |
Stage by AJCC 8th | |||
Earlier stage (≤ IIa) | 49 (28.5) | 24 (27.9) | 1.000 |
Later stage (> IIa) | 123 (71.5) | 62 (72.1) |